CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2026)
CV Sciences (CVSI) reported Total Non-Current Liabilities of $5.2 million for Q1 2026, down 10.99% on a YoY basis from $5.9 million in Q1 2025, and down 4.91% sequentially from $5.5 million in Q4 2025.
CV Sciences (CVSI) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 11 years of Total Non-Current Liabilities data on file, last reported at $5.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 10.99% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 10.99% YoY), and the FY2025 full-year result was $5.5 million, down 10.4% from the prior year.
- Total Non-Current Liabilities slipped to $5.2 million in Q1 2026, from $5.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $13.5 million in Q4 2022 to a low of $5.2 million in Q1 2026.
- A 5-year average of $6.6 million and a median of $6.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 54.18% in 2023 and decreased 0.97% in 2024, its largest moves.
- Tracing CVSI's Total Non-Current Liabilities over 5 years: stood at $13.5 million in 2022, then slumped by 54.18% to $6.2 million in 2023, then retreated by 0.97% to $6.1 million in 2024, then fell by 10.4% to $5.5 million in 2025, then decreased by 4.91% to $5.2 million in 2026.
- Business Quant data shows CVSI's Total Non-Current Liabilities at $5.2 million in Q1 2026, $5.5 million in Q4 2025, and $5.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 5.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.22 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 5.87 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Sep 30, 2024 | 6.16 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 6.19 Mn |
| Dec 31, 2022 | 13.51 Mn |
| Dec 31, 2020 | 19.41 Mn |
| Sep 30, 2020 | 18.96 Mn |
| Jun 30, 2020 | 23.71 Mn |
| Mar 31, 2020 | 21.94 Mn |
| Dec 31, 2019 | 23.13 Mn |
| Sep 30, 2019 | 23.00 Mn |
| Jun 30, 2019 | 17.37 Mn |
| Mar 31, 2019 | 17.08 Mn |
| Dec 31, 2018 | 6.79 Mn |